Heat Biologics EBIT

The latest EBIT for HTBX is $-43T as of September 2025. That compares with $-35M in the prior-year period — down 122015520.4% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Heat Biologics's historical trend and sector peers before judging valuation or financial health.

Over the past year, HTBX's EBIT moved from $-35M to $-43T — a 122015520.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Heat Biologics's operating scale or balance-sheet position.

Against Healthcare companies, HTBX currently prints $-43T for EBIT, while the sector average sits near $23B. That is roughly 188441.5% below the sector mean. Large gaps often invite a closer look at Heat Biologics's growth, margins, and balance sheet.

A EBIT figure of $-43T for HTBX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting HTBX's EBIT ($-43T), review year-over-year change from $-35M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.